Navigation Links
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival

portant, new therapeutic option for patients suffering from this devastating disease - both as first-line therapy and for patients who have failed chemotherapy. We are actively moving forward with a worldwide Phase 3 clinical trial in metastatic melanoma to confirm these results."

"The overall survival data from this randomized trial are impressive, particularly given the advanced stage of disease of these patients and the considerable improvement relative to what has previously been seen in this patient population. The apparent benefit to those patients who have progressed on chemotherapy is also impressive. These data, together with the previously reported results, represent the first positive blinded, randomized, controlled clinical trial for a new agent for metastatic melanoma in three decades, and provide a strong scientific basis for initiating the pivotal Phase 3 study," said Dr. Steven O'Day, Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles and principal investigator of the study. "There are few effective treatment options for patients and their physicians today and these exciting results for a novel drug candidate are welcome in the melanoma treatment community."

Based on the results of the Phase 2b trial and the significant unmet medical need for new treatment options for metastatic melanoma, the Food and Drug Administration (FDA) granted STA-4783 Fast Track designation in November, 2006. Synta plans to initiate a Phase 3 clinical trial to investigate STA-4783 as a first-line therapy for patients with metastatic melanoma in mid-2007. The trial will replicate the design of the Phase 2b trial, including the same primary endpoint, progression free survival, and the same treatment comparison, STA-4783 plus paclitaxel vs. paclitaxel alone.

"The incidence of melanoma has increased more rapidly than any other cancer during the past ten years and approximately 8,200 Americans wi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Synta Pharmaceuticals to Host Conference Call Today
2. Synta Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the ASCO Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... Data Expected in the Third Quarter --, SAN ... ), a biotechnology company focused on the development of,compounds ... has completed the last patient visit in its carotid ... analyzed to determine,VIA-2291,s effect on inflammation, and the company ...
... TOKYO, July 10 Sosei Group Corporation,("Sosei"; TSE ... completion of a Japanese Phase III clinical trial ... acquired the,exclusive distribution rights to the product in ... was designed to evaluate the safety and prevented,pregnancy ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Sosei Announces Completion of Phase III Trial for NorLevo(R) 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... special MRI methods, researchers have identified a pattern of ... (MCI) that indicates a greater likelihood of progression to ... edition of Radiology . , "Previously, this ... probable Alzheimer,s disease," said the study,s lead author, Linda ...
... Inc., today filed a formal protest and requested a ... managed behavioral health care contract RFP 09-630-7903-0001, which was ... New Mexico believes a stay is in the best ... consumers who will be adversely affected by the potential ...
... Feb. 9 The following is a statement from ... Director, American Public Health Association:"At a time when more ... to the nation,s public health system as a way ... (APHA) is thoroughly disappointed with the Senate,s decision to ...
... Inc. (NYSE Alternext: IMM) today announced results for its ... months ended December 31, 2008, revenues were $563,000, as ... 31, 2007. The decrease was primarily attributable to ... agreement. Loss from operations for the three months ...
... to Host Phoenix Arizona Celebrity GalaCOSTA MESA, Calif., Feb. 9 ... Dodgers, will co-host a celebrity casino event to benefit families ... Oakland A,s and World Series MVP. Kemp also serves ... (TACA). Kemp and Stewart host the celebrity-packed evening Ante ...
... ARLINGTON, Va., Feb. 9 BioInformatics, LLC ( http://www.gene2drug.com ... serving the life science industry -- will be a ... ( www.consumergeneticsshow.com ) in Boston, MA at the Hynes ... will also be exhibiting at the show. The ...
Cached Medicine News:Health News:MRI shows brain atrophy pattern that predicts Alzheimer's 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 2Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 3Health News:ValueOptions(R) New Mexico Files Formal Protest of Award of New Mexico Behavioral Health Contract to United 4Health News:APHA Urges Congress to Include Public Health Provision in Stimulus Bill 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 2Health News:Immtech Reports Fiscal Third Quarter 2009 Results 3Health News:Los Angeles Dodger Matt Kemp and Dave Stewart Top Celebrity List to Raise Funds for Autism 2Health News:BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009 2
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... ™ Airway., ,The LMA Flexible™ ... allows it to be positioned away ... a good seal. This makes it ... surgery, or other procedures where the ...
... The Most Versatile LMA™ Airway., ,The ... airway. The double cuff design enables seal ... be achieved. The drain tube separates the ... with the flexible airway tube, enable longer ...
Medicine Products: